Patents by Inventor Jin-Sook Jeong
Jin-Sook Jeong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240165072Abstract: The present invention relates to a pharmaceutical composition for alleviating or treating hair loss through the inflammation amelioration of human dermal papilla cells and peripheral cells and the inhibition of 5?-reductase expression, the pharmaceutical composition comprising genistein and kaempferol as active ingredients.Type: ApplicationFiled: March 22, 2022Publication date: May 23, 2024Inventors: Seung Sook LEE, Jong Moon JEONG, Min Jee LEE, Jin A SHIN, Hua LI
-
Publication number: 20240164170Abstract: A display device includes a plurality of pixels including a first pixel representing green, where each of the pixels includes a light emitting element including an anode, a light emitting layer, and a cathode. The display device further includes a control layer disposed in a direction in which the light emitting element emits light and overlapping the first pixel, and a transmittance of the control layer at a first wavelength band, within a green wavelength band, is lower than a transmittance at a remaining visible light region such that a decrease in a front luminance spectrum by the control layer is greater than a decrease in a side luminance spectrum by the control layer.Type: ApplicationFiled: October 20, 2023Publication date: May 16, 2024Inventors: Jin Sook BANG, Ilhoo PARK, Jinouk SONG, Sang Hoon YIM, Seong Jin JEONG
-
Publication number: 20240138242Abstract: A display device according to an embodiment includes: a substrate; a transistor on the substrate; a pixel electrode electrically connected to the transistor; a pixel defining layer on the pixel electrode and having a first opening overlapping the pixel electrode; an emission layer on the pixel electrode; a common electrode on the pixel definition layer and the emission layer; an encapsulation layer on the common electrode; a light extraction pattern on the encapsulation layer and having a first refractive index; and a reflection control layer covering the light extraction pattern and having a second refractive index different from the first refractive index.Type: ApplicationFiled: August 29, 2023Publication date: April 25, 2024Inventors: Jinouk SONG, Ilhoo PARK, Jin Sook BANG, Sang Hoon YIM, Seong Jin JEONG
-
Patent number: 11078487Abstract: A cancer-specific trans-splicing ribozyme and a use thereof are disclosed. The trans-splicing ribozyme does not act on normal tissue, but is specifically expressed in cancer tissue. Therefore, it is very safe and has excellent expression efficiency at the post-transcription level, and thus can be effectively used in treatment of cancer.Type: GrantFiled: February 21, 2020Date of Patent: August 3, 2021Assignees: Rznomics Inc., Dong-A University Research Foundation for Industry Academy Cooperation, Industry-Academic Cooperation Foundation, Dankook UniversityInventors: Seong-Wook Lee, Chang Ho Lee, Seung Ryul I Han, Ji Hyun Kim, Eun Yi Cho, Jin Sook Jeong, Mi Ha Ju
-
Publication number: 20200270612Abstract: A cancer-specific trans-splicing ribozyme and a use thereof are disclosed. The trans-splicing ribozyme does not act on normal tissue, but is specifically expressed in cancer tissue. Therefore, it is very safe and has excellent expression efficiency at the post-transcription level, and thus can be effectively used in treatment of cancer.Type: ApplicationFiled: February 21, 2020Publication date: August 27, 2020Applicants: Rznomics Inc., Dong-A University Research Foundation for Industry Academy Cooperation, Industry-Academic Cooperation Foundation, Dankook UniversityInventors: Seong-Wook Lee, Chang Ho Lee, Seung Ryul I Han, Ji Hyun Kim, Eun Yi Cho, Jin Sook Jeong, Mi Ha Ju
-
Patent number: 10280420Abstract: The present invention relates to a recombination vector, a transformation cell into which the recombinant vector is introduced, a ribozyme expressed from the recombination vector, a prophylactic or therapeutic composition for liver cancer comprising the recombination vector and the ribozyme, and a therapeutic method for liver cancer using the composition, said recombination vector comprising: a tissue-specific promoter; and a ribozyme-target gene expression cassette comprising a trans-splicing ribozyme targeting a cancer-specific gene and a target gene connected to the 3? exon of the ribozyme, wherein a splicing donor/splicing acceptor sequence (SD/SA sequence) is connected to the 5? end of the ribozyme-target gene expression cassette, woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) is connected to the 3? end of the ribozyme-target gene expression cassette, and a nucleic acid sequence recognizing a micro RNA-122a (microRNA-122a, miR-122a) is further connected to the 3? end of the WPRE.Type: GrantFiled: July 23, 2015Date of Patent: May 7, 2019Assignee: RZNOMICS INC.Inventors: Seong Wook Lee, Ju Hyun Kim, Jin Sook Jeong, Sang Young Han
-
Patent number: 10077430Abstract: The present invention relates to a recombinant adenovirus with increased in-vivo safety, tissue specificity, and anticancer activities, and a use thereof. Specifically, the recombinant adenovirus comprising: a promoter of the liver tissue-specific phosphoenolpyruvate carboxykinase (PEPCK) gene; a trans-splicing ribozyme which is operably linked to the promoter and acts on a cancer-specific gene; a therapeutic gene or a reporter gene which is linked to the 3? exon of the ribozyme; and a serotype 35 fiber knob and a serotype 5 shaft, in which the orf4 gene is deleted from adenovirus E1, E3 and E4 orf1, shows remarkable in-vivo safety, high specificity for a target tissue, and remarkable anticancer effects, and thus can be useful for an anticancer drug or a cancer diagnostic agent as a gene delivery vector.Type: GrantFiled: November 21, 2013Date of Patent: September 18, 2018Assignee: NATIONAL CANCER CENTERInventors: Sang Jin Lee, Yun-Hee Kim, In-Hoo Kim, Seong-Wook Lee, Jin-Sook Jeong, Sang Young Han
-
Publication number: 20180187188Abstract: The present invention relates to a recombination vector, a transformation cell into which the recombinant vector is introduced, a ribozyme expressed from the recombination vector, a prophylactic or therapeutic composition for liver cancer comprising the recombination vector and the ribozyme, and a therapeutic method for liver cancer using the composition, said recombination vector comprising: a tissue-specific promoter; and a ribozyme-target gene expression cassette comprising a trans-splicing ribozyme targeting a cancer-specific gene and a target gene connected to the 3? exon of the ribozyme, wherein a splicing donor/splicing acceptor sequence (SD/SA sequence) is connected to the 5? end of the ribozyme-target gene expression cassette, woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) is connected to the 3? end of the ribozyme-target gene expression cassette, and a nucleic acid sequence recognizing a micro RNA-122a (microRNA-122a, miR-122a) is further connected to the 3? end of the WPRE.Type: ApplicationFiled: July 23, 2015Publication date: July 5, 2018Inventors: Seong Wook Lee, Ju Hyun Kim, Jin Sook Jeong, Sang Young Han
-
Publication number: 20150337270Abstract: The present invention relates to a recombinant adenovirus with increased in-vivo safety, tissue specificity, and anticancer activities, and a use thereof. Specifically, the recombinant adenovirus comprising: a promoter of the liver tissue-specific phosphoenolpyruvate carboxykinase (PEPCK) gene; a trans-splicing ribozyme which is operably linked to the promoter and acts on a cancer-specific gene; a therapeutic gene or a reporter gene which is linked to the 3? exon of the ribozyme; and a serotype 35 fiber knob and a serotype 5 shaft, in which the orf4 gene is deleted from adenovirus E1, E3 and E4 orf1, shows remarkable in-vivo safety, high specificity for a target tissue, and remarkable anticancer effects, and thus can be useful for an anticancer drug or a cancer diagnostic agent as a gene delivery vector.Type: ApplicationFiled: November 21, 2013Publication date: November 26, 2015Inventors: Sang Jin LEE, Yun-Hee KIM, In-Hoo KIM, Seong-Wook LEE, Jin-Sook JEONG, Sang Young HAN
-
Patent number: 8927512Abstract: Provided are RNA aptamer specifically binding to cancer metastasis-inducing domain of CEA (Carcinoembryonic antigen), a composition for prevention and/or inhibition and/or diagnosis of cancer metastasis containing the same as an active ingredient, and a method of prevention and/or inhibition and/or diagnosis of cancer metastasis using the same.Type: GrantFiled: September 23, 2011Date of Patent: January 6, 2015Assignees: Postech Academy-Industry Foundation, PoscoInventors: Seong-Wook Lee, Young-Ju Lee, Jin-Sook Jeong
-
Publication number: 20140235698Abstract: Provided are RNA aptamer specifically binding to cancer metastasis-inducing domain of CEA (Carcinoembryonic antigen), a composition for prevention and/or inhibition and/or diagnosis of cancer metastasis containing the same as an active ingredient, and a method of prevention and/or inhibition and/or diagnosis of cancer metastasis using the same.Type: ApplicationFiled: September 23, 2011Publication date: August 21, 2014Applicants: POSCO, POSTECH ACADEMY-INDUSTRY FOUNDATIONInventors: Seong-Wook LEE, Young-Ju Lee, Jin-Sook Jeong
-
Patent number: 8673573Abstract: Disclosed are a cancer marker-detecting composition comprising an agent for measuring an mRNA or protein expression level of eIF3m, a cancer diagnosis kit comprising the same, a method for detecting an eIF3m polynucleotide or protein by treating a biological specimen with the agent to detect a substance binding specifically to the agent and quantitatively comparing the substance between a subject and a normal control, and a method for the treatment and prevention of cancer comprising an agent for down-regulating the expression of an eIF3m polynucleotide or protein.Type: GrantFiled: October 7, 2010Date of Patent: March 18, 2014Assignee: National Cancer CenterInventors: Yeon-Su Lee, Sung-Ho Goh, Sung-Hye Hong, In-Hoo Kim, Jin-Sook Jeong
-
Patent number: 8541237Abstract: Disclosed herein is a composition for molecular imaging comprising a trans-splicing ribozyme coupled with an imaging reporter gene. The trans-splicing ribozyme targets a specific gene associated with a disease. Also disclosed is a molecular imaging method using the composition.Type: GrantFiled: October 26, 2007Date of Patent: September 24, 2013Assignee: National Cancer CenterInventors: In-Hoo Kim, Seong-Wook Lee, Seung-Hee Hong, Jin-Sook Jeong, Yoon-Jong Lee, Yeon-Su Lee, Haeng-Im Jung
-
Publication number: 20120201837Abstract: Disclosed are a cancer marker-detecting composition comprising an agent for measuring an mRNA or protein expression level of eIF3m, a cancer diagnosis kit comprising the same, a method for detecting an eIF3m polynucleotide or protein by treating a biological specimen with the agent to detect a substance binding specifically to the agent and quantitatively comparing the substance between a subject and a normal control, and a method for the treatment and prevention of cancer comprising an agent for down-regulating the expression of an eIF3m polynucleotide or protein.Type: ApplicationFiled: October 7, 2010Publication date: August 9, 2012Applicant: NATIONAL CANCER CENTERInventors: Yeon-Su Lee, Sung-Ho Goh, Sung-Hye Hong, In-Hoo Kim, Jin-Sook Jeong
-
Publication number: 20110256524Abstract: Disclosed herein are a recombinant adenovirus comprising tissue-specific promoters and trans-splicing ribozymes targeting tumor-specific genes, and uses thereof. More specifically, disclosed herein are a recombinant adenovirus comprising (1) a tissue-specific promoter, (2) a trans-splicing ribozyme acting on tumor-specific genes operably linked to the promoter, and (3) a therapeutic or reporter gene linked to 3? exon of the ribozyme, an anticancer pharmaceutical composition comprising the same, and a composition for cancer diagnosis comprising the same. The recombinant adenovirus exhibits high specificity and significantly improved therapeutic efficacy to gene targeted tissues. Accordingly, the recombinant adenovirus is useful as a gene delivery vector for anticancer agents or cancer diagnostics.Type: ApplicationFiled: August 27, 2008Publication date: October 20, 2011Applicant: Industry-Academic Cooperation Foundation, Dankook UniversityInventors: Seong-Wook Lee, Min-Sun Song, In-Hoo Kim, Jin-Sook Jeong
-
Publication number: 20110184042Abstract: Provided are RNA aptamer specifically binding to cancer metastasis-inducing domain of CEA (Carcinoembryonic antigen), a composition for prevention and/or inhibition and/or diagnosis of cancer metastasis containing the same as an active ingredient, and a method of prevention and/or inhibition and/or diagnosis of cancer metastasis using the same.Type: ApplicationFiled: March 17, 2010Publication date: July 28, 2011Applicants: POSTECH ACADEMY-INDUSTRY FOUNDATION, POSCOInventors: SEONG-WOOK LEE, YOUNG-JU LEE, JIN-SOOK JEONG
-
Publication number: 20110165690Abstract: Disclosed herein is a composition for molecular imaging comprising a trans-splicing ribozyme coupled with an imaging reporter gene. The trans-splicing ribozyme targets a specific gene associated with a disease. Also disclosed is a molecular imaging method using the composition.Type: ApplicationFiled: October 26, 2007Publication date: July 7, 2011Inventors: In-Hoo Kim, Seong-Wook Lee, Seung-Hee Hong, Jin-Sook Jeong, Yeon-Su Lee, Haeng-Im Jung